EAPH — Easton Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $2.48m
Annual income statement for Easton Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2011 December 31st | 2012 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | 10-K | 10-K | 10-K |
| Standards: | — | — | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.379 | 1.56 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0.107 | 0.2 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.113 | 0.183 | 0.503 | 1.88 | 0.189 |
| Operating Profit | -0.113 | -0.183 | -0.124 | -0.323 | -0.189 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.113 | -0.183 | -0.169 | -0.323 | -0.189 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.113 | -0.183 | -0.169 | -0.323 | -0.189 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.113 | -0.183 | -0.169 | -0.323 | -0.189 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -0.113 | -0.183 | -0.169 | -0.323 | -0.189 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.001 | -0.002 | -0 | -0 | -0 |
| Dividends per Share |